Aida Pharmaceuticals IncOver The Counter Market:AIDA
- LAST PRICE0.0002
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0002
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aida Pharmaceuticals Inc | 5.4K | 0.0x | --- |
Tibet Pharmaceuticals Inc | 10.0 | 0.0x | --- |
Aoxing Pharmaceutical Company Inc | 1.7M | -0.3x | --- |
Clever Leaves Holdings Inc | 6.8M | -0.3x | --- |
Cumberland Pharmaceuticals Inc | 24.1M | -4.0x | --- |
Hanyuan Biotech International Inc | 539.4K | 0.0x | --- |
Company Information
AIDA Pharmaceuticals, Inc., located in Hangzhou, the People’s Republic of China, operates through its subsidiaries, which include Earjoy Group Limited (Earjoy), Hangzhou Aida Pharmaceutical Co., Ltd (Hangzhou Aida), Hangzhou Boda Medical Research and Development Co., Ltd. (Boda), Hainan Aike Pharmaceutical Co., Ltd. (Aike), Changzhou Fangyuan Pharmaceutical Co., Ltd. (Fangyuan) and Shanghai Qiaer Bio-technology Co., Ltd (Qiaer). Earjoy is an investment holding company. Hangzhou Aida is a pharmaceutical company engaged in the development, manufacture, marketing, licensing, and distribution of pharmaceutical products primarily in mainland China. Hangzhou Aida has a total of nine production lines for the manufacture of antibiotics, cardiovascular and anti-tumor drugs in various forms, including injectable powder, injectable liquid, capsules, tablets and ointments. Hangzhou Aida’s primary product is the injectable powder form of Etimicin Sulfate.
Contact Information
- Headquarters
- 31 Dingjiang Road, Jianggan DistrictHANGZHOU, ZHJ, China 310016
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Biao Jin
- Chief Financial Officer
- Hui Lin
- Secretary
- Yuejun Jiang
- Director
- Jiajun Qiu
- Director
- Qiong Zhang
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.4K |
|---|---|
Revenue (TTM) | $40.5M |
Shares Outstanding | 27.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.08 |
Book Value | $0.49 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | 0.0x |
Operating Margin | 0.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
